STRIKING
VISUALIZATION
indigo carmine is back!FDA APPROVEDSee Bludigo in Action >
THE FIRST AND ONLY
FDA-APPROVED
injectable indigo carmine
diagnostic dye2
Request a Rep >
FAST DETECTIONwithin 4-9 minutes
post-IV injection2
Review the Data >Urine jet post-Bludigo application1

Come See Us

Spring IDN Summit & Reverse Expo 2024

April 15-17, 2024
Orlando, FL

More Info

STRIKING
VISUALIZATION
indigo carmine is back!FDA APPROVEDSee Bludigo in Action >
THE FIRST AND ONLY
FDA-APPROVED
injectable indigo
carmine
diagnostic dye2
Request a Rep >
FAST
DETECTION
within 4-9 minutes
post-IV injection2
Review the Data >Urine jet post-
Bludigo application1

Come See Us

Spring IDN Summit & Reverse Expo 2024

April 15-17, 2024
Orlando, FL

More Info

The Bludigo Difference

DEEP BLUE COLOR1

Significantly aids visualization when assessing ureter patency

FDA APPROVED2

The first and only FDA-approved injectable indigo carmine diagnostic dye

FAST DETECTION2

Within 4-9 minutes post-IV injection

BLUDIGO (indigotindisulfonate sodium injection, USP)

INDICATIONS AND USAGE

BLUDIGO is a diagnostic dye indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BLUDIGO is contraindicated in patients with known hypersensitivity to indigotindisulfonate or any of its components.

WARNINGS AND PRECAUTIONS

Cardiovascular Reactions: Severe or life-threatening cardiovascular reactions including cardiac arrest, arrhythmia, asystole, atrioventricular block second degree, hypotension, elevation in blood pressure, bradycardia, and tachycardia have been reported. Closely monitor blood pressure and cardiac rhythm during and following the BLUDIGO injection. Interrupt administration if reactions are observed.

Hypersensitivity Reactions: Serious anaphylactic reactions with hypotension, dyspnea, bronchospasm, urticaria, or erythema have been reported. Monitor patients for anaphylactic reactions and have emergency equipment and trained personnel readily available.

Interference with Oximetry Measurements: Anesthesiologists should be aware of the potential for artifactual reduction in SpO2 when anesthetized patients are administered BLUDIGO.

USE IN SPECIFIC POPULATIONS

Renal Impairment: BLUDIGO is not recommended for use in patients with eGFR<30 mL/min.

Pediatric Use: The safety and effectiveness of BLUDIGO have not been established in pediatric patients.

Pregnancy and Lactation: Please consult the Full Prescribing Information before using BLUDIGO in a patient that is lactating, pregnant, or may be pregnant.

RECOMMENDED DOSAGE

The recommended dose for BLUDIGO is 5 mL given intravenously over 1 minute.

IMPORTANT ADMINISTRATION INSTRUCTIONS

  • Monitor blood pressure and cardiac rhythm during and following the injection.
  • Use immediately after opening ampule.
  • Withdraw the contents of the ampule through a 5 micron or smaller filter straw/filter needle to ensure that the withdrawn solution contains no particulates. The withdrawn solution should be inspected visually for particulate matter and discoloration prior to administration.
  • Do not administer with infusion assemblies used with other diluents or drugs.
  • Discard any unused portion.

ADVERSE REACTIONS

Clinical Trial Experience: The most common adverse reactions (1%) associated with BLUDIGO in clinical trials were: constipation, nausea, vomiting, abdominal pain, pyrexia, ALT increase, and dysuria.

Postmarketing Experience: The following adverse reactions have been identified following the use of indigotindisulfonate sodium injection products:

  • Cardiovascular disorders: cardiac arrest, arrhythmia, asystole, atrioventricular block second degree, hypotension, elevation in blood pressure, bradycardia, tachycardia
  • General disorders and administration site conditions: injection site discoloration
  • Immune system disorders: anaphylactic reactions with hypotension, dyspnea, bronchospasm, urticaria, erythema

Please see the full Prescribing Information for additional Important Safety Information.

To report SUSPECTED ADVERSE REACTIONS, contact PROVEPHARM Inc at 1–833-727-6556 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. Data on file. PVP-10ICO1 clinical study report. Newark, NJ: Provepharm, Inc.; 2024. 2. Bludigo. Prescribing Information. Provepharm, Inc.; 2024.